0000721371-20-000042.txt : 20200511 0000721371-20-000042.hdr.sgml : 20200511 20200511065816 ACCESSION NUMBER: 0000721371-20-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 20862543 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 8-K 1 a20q38k33120form8-knew.htm 8-K Document
false0000721371 0000721371 2020-05-11 2020-05-11
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2020
 
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
 
 
 
Ohio
1-11373
 
31-0958666
(State or other
jurisdiction of incorporation)
(Commission
File Number)

 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
 
 
 
7000 Cardinal Place, Dublin, Ohio 43017
(614) 757-5000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common shares (without par value)
CAH
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   p

 


Item 2.02: Results of Operations and Financial Condition
On May 11, 2020, Cardinal Health, Inc. (the "Company") issued a news release announcing its results for the quarter ended March 31, 2020. A copy of the news release is included as Exhibit 99.1 to this report.
Item 7.01: Regulation FD Disclosure
During a webcast scheduled to be held at 8:30 a.m. Eastern time on May 11, 2020, the Company's Chief Executive Officer and Chief Financial Officer will discuss the Company's results for the quarter ended March 31, 2020 and outlook for the fiscal year ending June 30, 2020. The slide presentation for the webcast will be available on the Investors page at ir.cardinalhealth.com. An audio replay of the webcast also will be available on the Investors page at ir.cardinalhealth.com.
Item 9.01: Financial Statements and Exhibits
(d) Exhibits



2


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Cardinal Health, Inc.
 
 
(Registrant)
 
 
 
 
Date:
May 11, 2020
By:
/s/    DAVID C. EVANS
 
 
 
David C. Evans
 
 
 
Chief Financial Officer


3
 EX-99.1 2 a20q38k33120exhibit991.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1

essentialtocarea40.jpg
FOR IMMEDIATE RELEASE
Media:
Sarah Shew
 
Investors:
Kevin Moran
 
(614) 553-3401
 
 
(614) 757-7942
 
Sarah.Shew@cardinalhealth.com
 
 
Kevin.Moran@cardinalhealth.com

Cardinal Health Reports Third Quarter Results for Fiscal Year 2020

•
Revenue increased 11% to $39.2 billion

•
GAAP operating earnings increased 30% to $562 million, non-GAAP operating earnings increased 8% to $719 million

•
Company reaffirms FY20 guidance

DUBLIN, Ohio, May 11, 2020 - Cardinal Health (NYSE: CAH) today reported financial results for the third quarter of fiscal 2020 ended March 31, 2020.Third quarter revenue was $39.2 billion, an increase of 11% from the third quarter of last year.

Third quarter GAAP operating earnings increased 30% to $562 million. Non-GAAP operating earnings increased 8% to $719 million. GAAP diluted earnings per share (EPS) increased 20% to $1.19, while non-GAAP diluted EPS increased 2% to $1.62.

“I want to express my gratitude to our employees and our partners across the healthcare industry for their incredible efforts to help us perform our critical role in the supply chain during this unprecedented time,” said Mike Kaufmann, CEO of Cardinal Health. “We remain committed to delivering products and solutions to front-line health care providers so they can safely serve and treat patients around the world. As we look toward and beyond the fourth quarter, we will continue to take strategic actions to fulfill this mission.”

Q3 FY20 summary
 
Q3 FY20
 
Q3 FY19
 
Y/Y
Revenue
$
39.2
 billion
 
$
35.2
 billion
 
11%
Operating earnings
$
562
 million
 
$
432
 million
 
30%
Non-GAAP operating earnings
$
719
 million
 
$
667
 million
 
8%
Net earnings attributable to Cardinal Health, Inc.
$
350
 million
 
$
296
 million
 
18%
Non-GAAP net earnings attributable to Cardinal Health, Inc.
$
474
 million
 
$
475
 million
 
—%
Diluted EPS attributable to Cardinal Health, Inc.
$
1.19

 
$
0.99

 
20%
Non-GAAP diluted EPS attributable to Cardinal Health, Inc.
$
1.62

 
$
1.59

 
2%

During the third quarters of fiscal 2020 and 2019, GAAP effective tax rates were 26.8% and 20.0%, respectively. Non-GAAP effective tax rates were 25.7% and 21.6%, respectively.












Cardinal Health
Page 2

Segment results

Pharmaceutical segment
 
Q3 FY20
 
Q3 FY19
 
Y/Y
Revenue
$
35.1
 billion
 
$
31.4
 billion
 
12%
Segment profit
$
534
 million
 
$
536
 million
 
—%
Third quarter revenue for the Pharmaceutical segment increased 12 percent to $35.1 billion, due to sales growth from Pharmaceutical Distribution customers and, to a lesser extent, Specialty Solutions customers. This growth included an acceleration in overall pharmaceutical sales in March, which the company believes was due to the COVID-19 pandemic.

Pharmaceutical segment profit was flat at $534 million in the third quarter. This reflects strong performance in the company’s generics program and the adverse impact of Pharmaceutical Distribution customer contract renewals.

Medical segment
 
Q3 FY20
 
Q3 FY19
 
Y/Y
Revenue
$
4.1
 billion
 
$
3.9
 billion
 
5%
Segment profit
$
178
 million
 
$
155
 million
 
15%
Third quarter revenue for the Medical segment increased 5 percent to $4.1 billion, due to growth in products and distribution and Cardinal Health at Home.

Medical segment profit increased 15 percent to $178 million in the third quarter due to an increase in products and distribution, including benefits from global manufacturing and cost savings initiatives.

Fiscal year 2020 Outlook
While both segments experienced a modest net positive impact in the third quarter from increased volume related to the COVID-19 pandemic, the company expects a significant net negative impact to fourth quarter financial results in both segments. This is driven most meaningfully by a decrease in volume related to the cancellation or deferral of elective medical procedures.

The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

The company reaffirms its fiscal year 2020 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. of $5.20 to $5.40.

Recent highlights
•
Jason Hollar joined the company on April 27 and will become Chief Financial Officer on May 26. Jason previously served as CFO of Tenneco Inc. and Sears Holdings Corporation.
•
Cardinal Health board of directors approved a quarterly dividend of $0.4859 per share. The dividend will be payable on July 15, 2020 to shareholders of record at the close of business on July 1, 2020.
•
The company was recognized as a “2020 NAFE Top Companies for Executive Women" by the National Association for Female Executives for the ninth consecutive year.

Webcast
Cardinal Health will host a webcast today at 8:30 a.m. Eastern to discuss third quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.

Presentation slides and a webcast replay will be available until May 10, 2021.





Cardinal Health
Page 3


About Cardinal Health
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company enhances supply chain efficiency for clinically proven medical products, pharmaceuticals and cost-effective solutions. To combat prescription drug misuse, the Cardinal Health Foundation and its education partners created Generation Rx, a national drug prevention education and awareness program. The Foundation actively supports an array of other solutions, including efforts to reduce opioid prescribing, promote drug take back and safe disposal and expand collaborative community work.
Cardinal Health is backed by nearly 100 years of experience with operations in nearly 46 countries. For more information, visit cardinalhealth.com. Follow us on Twitter, Facebook and LinkedIn.

1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions Concerning Forward-Looking Statements
This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture with CVS Health and other components of our generics pharmaceutical program; risks associated with the distribution of opioids, including potential financial impact associated with the outcome of the ongoing lawsuits and investigations by certain governmental and regulatory authorities and the risks associated with the ongoing global settlement framework discussions, including the risk that we may fail to reach a settlement agreement or that a final settlement could require us to pay more than we currently anticipate; risks arising from the ongoing COVID-19 pandemic and our critical role in the global healthcare supply chain, including the possibility that continued deferrals and cancellations of elective medical procedures will result in a sustained reduction in demand for our products and the possibility of product shortages or supply disruptions from either new international regulations or forced shut downs of distribution or manufacturing facilities; risks associated with the recent recalls of our surgical gowns and affected Presource Packs, including the possibility of government investigations or actions by regulators which could result suspension of our ability to produce, distribute or sell products and civil or criminal sanction; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; risks associated with our ability to improve the performance of our Medical segment’s Cardinal Health Brand Products business; uncertainties due to government health care reform; and risks associated with our cost savings initiatives, including the possibility that they could result in greater charges or expenses than we anticipate, could fail to achieve the desired efficiencies or strategic outcomes and could have unintended consequences, such as business disruption. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of May 11, 2020. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.





Schedule 1
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (Unaudited)
 
Third Quarter
 
Year-to-Date
(in millions, except per common share amounts)
2020

2019
 
% Change
 
2020
 
2019
 
% Change
Revenue
$
39,157

 
$
35,228

 
11
 %
 
$
116,233

 
$
108,181

 
7
 %
Cost of products sold
37,272

 
33,464

 
11
 %
 
110,955

 
103,021

 
8
 %
Gross margin
1,885

 
1,764

 
7
 %
 
5,278

 
5,160

 
2
 %
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
Distribution, selling, general and administrative expenses
1,165

 
1,097

 
6
 %
 
3,435

 
3,315

 
4
 %
Restructuring and employee severance
(6
)
 
53

 
 
 
80

 
97

 
 
Amortization and other acquisition-related costs
130

 
154

 
 
 
395

 
468

 
 
Impairments and (gain)/loss on disposal of assets, net
(1
)
 
11

 
 
 
7

 
(492
)
 
 
Litigation (recoveries)/charges, net 1
35

 
17

 
 
 
5,729

 
20

 
 
Operating earnings/(loss)
562

 
432

 
30
 %
 
(4,368
)
 
1,752

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense, net
19

 
(13
)
 
 
 
21

 
13

 
 
Interest expense, net
60

 
75

 
(20
)%
 
189

 
227

 
(17
)%
Loss on extinguishment of debt
5

 
—

 
 
 
9

 
—

 
 
Earnings/(loss) before income taxes
478

 
370

 
29
 %
 
(4,587
)
 
1,512

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Provision for/(benefit from) income taxes 2
127

 
74

 
72
 %
 
(237
)
 
342

 
N.M.

Net earnings/(loss)
351

 
296

 
19
 %
 
(4,350
)
 
1,170

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Less: Net earnings attributable to noncontrolling interests
(1
)
 
—

 
 
 
(2
)
 
(1
)
 
 
Net earnings/(loss) attributable to Cardinal Health, Inc.
$
350

 
$
296

 
18
 %
 
$
(4,352
)
 
$
1,169

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:
 
 
 
 
 
 
 
 
 
 
 
Basic
$
1.20

 
$
0.99

 
21
 %
 
$
(14.84
)
 
$
3.89

 
N.M.

Diluted
1.19

 
0.99

 
20
 %
 
(14.84
)
3 

3.88

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
 
 
 
 
Basic
292

 
298

 
 
 
293

 
301

 
 
Diluted
294

 
299

 
 
 
293

3 

302

 
 
1 Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions. The amount of ultimate loss may differ materially from this accrual.
2 In connection with these matters, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, during the first quarter of fiscal 2020, reflecting our current assessment of the estimated future deductibility of the amount that may be paid under the $5.63 billion accrual taken in connection with the opioid litigation. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.
3 Due to the net loss for the nine months ended March 31, 2020, potentially dilutive common shares have not been included in the denominator of the dilutive per share computation due to their anti-dilutive effect.



Schedule 2
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
(in millions)
March 31,
2020
 
June 30,
2019
Assets
 
 
 
Current assets:
 
 
 
Cash and equivalents
$
2,329

 
$
2,531

Trade receivables, net
9,019

 
8,448

Inventories, net
12,808

 
12,822

Prepaid expenses and other
1,692

 
1,946

Total current assets
25,848

 
25,747

 
 
 
 
Property and equipment, net
2,299

 
2,356

Goodwill and other intangibles, net
11,378

 
11,808

Other assets
1,623

 
1,052

Total assets
$
41,148

 
$
40,963

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
21,984

 
$
21,535

Current portion of long-term obligations and other short-term borrowings
508

 
452

Other accrued liabilities
2,179

 
2,122

Total current liabilities
24,671

 
24,109

 
 
 
 
Long-term obligations, less current portion
6,754

 
7,579

Deferred income taxes and other liabilities
8,517

 
2,945

 
 
 
 
Total shareholders’ equity
1,206

 
6,330

Total liabilities and shareholders’ equity
$
41,148

 
$
40,963




Schedule 3
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
Third Quarter
 
Year-to-Date
(in millions)
2020
 
2019
 
2020
 
2019
Cash flows from operating activities:
 
 
 
 
 
 
 
Net earnings/(loss)
$
351

 
$
296

 
$
(4,350
)
 
$
1,170

 
 
 
 
 
 
 
 
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
224

 
261

 
688

 
759

Impairments and loss on sale of other investments
—

 
—

 
—

 
2

Impairments and (gain)/loss on disposal of assets, net
(1
)
 
11

 
7

 
(492
)
Loss on extinguishment of debt
5

 
—

 
9

 
—

Share-based compensation
27

 
23

 
68

 
64

Provision for bad debts
39

 
19

 
86

 
59

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
 
 
 
 
 
 
 
(Increase)/decrease in trade receivables
(774
)
 
35

 
(653
)
 
(156
)
(Increase)/decrease in inventories
983

 
408

 
(8
)
 
(345
)
Increase/(decrease) in accounts payable
525

 
(95
)
 
448

 
846

Other accrued liabilities and operating items, net
297

 
522

 
5,425

 
309

Net cash provided by operating activities
1,676

 
1,480

 
1,720

 
2,216

 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
Acquisition of subsidiaries, net of cash acquired
—

 
(17
)
 
—

 
(38
)
Additions to property and equipment
(90
)
 
(76
)
 
(239
)
 
(192
)
Purchases of investments
(12
)
 
(1
)
 
(18
)
 
(11
)
Proceeds from sale of investments
4

 
1

 
6

 
3

Proceeds from divestitures, net of cash sold, and disposal of property and equipment
—

 
9

 
2

 
749

Net cash provided by/(used in) investing activities
(98
)
 
(84
)
 
(249
)
 
511

 
 
 
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
 
 
 
Net change in short-term borrowings
(683
)
 
—

 
(2
)
 
—

Reduction of long-term obligations, net of issuance costs
(95
)
 
—

 
(888
)
 
(2
)
Net tax proceeds/(withholdings) from share-based compensation
7

 
—

 
(4
)
 
(13
)
Dividends on common shares
(141
)
 
(142
)
 
(428
)
 
(435
)
Purchase of treasury shares
—

 
—

 
(350
)
 
(600
)
Net cash used in financing activities
(912
)
 
(142
)
 
(1,672
)
 
(1,050
)
 
 
 
 
 
 
 
 
Effect of exchange rates changes on cash and equivalents
4

 
2

 
(1
)
 
(2
)
 
 
 
 
 
 
 
 
Net increase/(decrease) in cash and equivalents
670

 
1,256

 
(202
)
 
1,675

Cash and equivalents at beginning of period
1,659

 
2,182

 
2,531

 
1,763

Cash and equivalents at end of period
$
2,329

 
$
3,438

 
$
2,329

 
$
3,438





Schedule 4
Cardinal Health, Inc. and Subsidiaries
Segment Information


    
Third Quarter
 
 
 
 
 
 
 
 
 
(in millions)
2020
 
2019
 
(in millions)
2020
 
2019
Pharmaceutical
 
 
 
 
Medical
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
Revenue
 
 
 
Amount
$
35,112

 
$
31,361

 
Amount
$
4,051

 
$
3,871

Growth rate
12
 %
 
6
 %
 
Growth rate
5
%
 
(1
)%
 
 
 
 
 
 
 
 
 
Segment profit
 
 
 
 
Segment profit
 
 
 
Amount
$
534

 
$
536

 
Amount
$
178

 
$
155

Growth rate
—
 %
 
(10
)%
 
Growth rate
15
%
 
(22
)%
Segment profit margin
1.52
 %
 
1.71
 %
 
Segment profit margin
4.39
%
 
4.01
 %
Year-to-Date
 
 
 
 
 
 
 
 
 
(in millions)
2020
 
2019
 
(in millions)
2020
 
2019
Pharmaceutical
 
 
 
 
Medical
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
Revenue
 
 
 
Amount
$
104,254

 
$
96,516

 
Amount
$
11,991

 
$
11,678

Growth rate
8
%
 
7
 %
 
Growth rate
3
%
 
—
 %
 
 
 
 
 
 
 
 
 
Segment profit
 
 
 
 
Segment profit
 
 
 
Amount
$
1,394

 
$
1,388

 
Amount1
$
543

 
$
479

Growth rate
—
%
 
(12
)%
 
Growth rate
13
%
 
(13
)%
Segment profit margin
1.34
%
 
1.44
 %
 
Segment profit margin
4.53
%
 
4.10
 %
1 Medical segment profit for the nine months ended March 31, 2020 does not include $95 million incurred for inventory write-offs and certain remediation and supply disruption costs associated with the recently announced voluntary surgical gown-related recalls.



Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1 

 
 












 
Gross



Operating
Earnings


Net


Diluted

 
Margin

SG&A2

Earnings
Before
Provision for

Earnings3
Effective

EPS3

Gross
Growth

Growth
Operating
Growth
Income
Income
Net
Growth
Tax
Diluted
Growth
(in millions, except per common share amounts)
Margin
Rate
SG&A2
Rate
Earnings
Rate
Taxes
Taxes
Earnings3
Rate
Rate
EPS3
Rate
Third Quarter 2020
GAAP
$
1,885

7
 %
$
1,165

6
 %
$
562

30
 %
$
478

$
127

$
350

18
 %
26.8
%
$
1.19

20
%
Surgical gown recall costs
(1
)
 
—

 
(1
)
 
(1
)
—

(1
)
 
 
—

 
Restructuring and employee severance
—

 
—


(6
)

(6
)
(3
)
(3
)


(0.01
)

Amortization and other acquisition-related costs
—

 
—


130


130

31

99



0.34


Impairments and (gain)/loss on disposal of assets, net
—

 
—


(1
)

(1
)
(1
)
—



—


Litigation (recoveries)/charges, net
—

 
—


35


35

8

27



0.09


Loss on extinguishment of debt
—

 
—


—


5

1

4





0.01



Transitional tax benefit, net
—

 
—


—


—

1

(1
)




—



Non-GAAP
$
1,884

7
 %
$
1,165

6
 %
$
719

8
 %
$
639

$
164

$
474

—
 %
25.7
%
$
1.62

2
%

Third Quarter 2019
GAAP
$
1,764

(8
)%
$
1,097

(3
)%
$
432

(21
)%
$
370

$
74

$
296

16
 %
20.0
%
$
0.99

22
%
Restructuring and employee severance
—

 
—


53


53

14

39



0.13


Amortization and other acquisition-related costs
—

 
—


154


154

38

116



0.39


Impairments and (gain)/loss on disposal of assets, net
—

 
—


11


11

4

7



0.03


Litigation (recoveries)/charges, net
—

 
—


17


17

7

10



0.03


Transitional tax benefit, net
—

 
—


—


—

(5
)
5



0.02


Non-GAAP
$
1,764

(8
)%
$
1,097

(3
)%
$
667

(15
)%
$
605

$
130

$
475

9
 %
21.6
%
$
1.59

14
%
1For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2Distribution, selling, general and administrative expenses.
3Attributable to Cardinal Health, Inc.
The sum of the components may not equal the total due to rounding.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.














Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1 

 
 



Operating
Earnings/


Net




 
Gross



Earnings/
(Loss)
Provision for/

Earnings/


Diluted

 
Margin

SG&A2
Operating
(Loss)
Before
(Benefit from)
Net
(Loss)3
Effective

EPS3

Gross
Growth

Growth
Earnings/
Growth
Income
Income
Earnings/
Growth
Tax
Diluted
Growth
(in millions, except per common share amounts)
Margin
Rate
SG&A2
Rate
(Loss)
Rate
Taxes
Taxes
(Loss)3
Rate
Rate
EPS3,4
Rate
Year-to-Date 2020
GAAP
$
5,278

2
 %
$
3,435

4
 %
$
(4,368
)
N.M

$
(4,587
)
$
(237
)
$
(4,352
)
N.M

5.2
%
$
(14.84
)
N.M

Surgical gown recall costs
55

 
(40
)
 
95

 
95

25

70

 
 
0.24

 
State opioid assessment related to prior fiscal years
—

 
(4
)

4


4

1

3



0.01


Restructuring and employee severance
—

 
—


80


80

18

62



0.21


Amortization and other acquisition-related costs
—

 
—


395


395

98

297



1.01


Impairments and (gain)/loss on disposal of assets, net
—

 
—


7


7

1

6



0.02


Litigation (recoveries)/charges, net5
—

 
—


5,729


5,729

509

5,220



17.80


Loss on extinguishment of debt
—

 
—


—


9

2

7



0.02


Transitional tax benefit, net
 
 
—


—


—

12

(12
)


(0.04
)

Non-GAAP
$
5,333

3
 %
$
3,391

2
 %
$
1,942

5
 %
$
1,732

$
429

$
1,300

4
 %
24.8
%
$
4.41

6
 %

Year-to-Date 2019
GAAP
$
5,160

(5
)%
$
3,315

—
 %
$
1,752

45
 %
$
1,512

$
342

$
1,169

(18
)%
22.6
%
$
3.88

(14
)%
Restructuring and employee severance
—

 
—


97


97

25

72



0.24


Amortization and other acquisition-related costs
—

 
—


468


468

112

356



1.18


Impairments and (gain)/loss on disposal of assets, net
—

 
—


(492
)

(492
)
(129
)
(363
)


(1.20
)

Litigation (recoveries)/charges, net
—

 
—


20


20

7

13



0.04


Transitional tax benefit, net
—

 
—


—


—

(8
)
8



0.03


Non-GAAP
$
5,160

(5
)%
$
3,315

—
 %
$
1,845

(13
)%
$
1,605

$
349

$
1,255

—
 %
21.7
%
$
4.17

5
 %
1For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2Distribution, selling, general and administrative expenses.
3Attributable to Cardinal Health, Inc.
4For the nine months ended March 31, 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Year-to-date fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.
5Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 related to the opioid litigation.
The sum of the components may not equal the total due to rounding.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.


Cardinal Health, Inc. and Subsidiaries

Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP").
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and, in most cases, determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
Surgical gown recall costs includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the fiscal year of the initial assessment. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when certain assessments were found by a Court unconstitutional.
•
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.
•
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•
Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•
Loss on extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
•
Transitional tax benefit, net related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.


The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.


Forward Looking Non-GAAP Measures
In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.
The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company’s fiscal 2020 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company’s EPS from $0.75 to $4.19, which includes a goodwill impairment charge of $4.36 per share related to our Medical segment that we recognized in fiscal 2018. The excluded items for fiscal 2020 year to date period impacted the Company's EPS by $19.25, which includes a $17.53 charge related to the opioid litigation.

Definitions

Growth rate calculation: growth rates in this earnings release are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits) and surgical gown recall costs.
Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and surgical gown recall costs.
Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, and (8) loss on extinguishment of debt.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on extinguishment of debt, each net of tax, and (9) transitional tax benefit, net.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on extinguishment of debt, and (9) transitional tax benefit, (net) divided by (earnings/(loss) before income taxes adjusted for the first eight items).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.


 EX-101.SCH 3 cah-20200511.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 cah-20200511_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 cah-20200511_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cah-20200511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 cah-20200511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 essentialtocarea40.jpg begin 644 essentialtocarea40.jpg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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 a20q38k33120form8-knew_htm.xml IDEA: XBRL DOCUMENT 0000721371 2020-05-11 2020-05-11 false 0000721371 8-K 2020-05-11 Cardinal Health, Inc. OH 1-11373 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 false false false false Common shares (without par value) CAH NYSE false ZIP 12 0000721371-20-000042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-20-000042-xbrl.zip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inancial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports a20q38k33120form8-knew.htm a20q38k33120exhibit991.htm cah-20200511.xsd cah-20200511_cal.xml cah-20200511_def.xml cah-20200511_lab.xml cah-20200511_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page
May 11, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 11, 2020
Entity Registrant Name Cardinal Health, Inc.
Entity Incorporation, State or Country Code OH
Entity File Number 1-11373
Entity Tax Identification Number 31-0958666
Entity Address, Address Line One 7000 Cardinal Place
Entity Address, City or Town Dublin
Entity Address, State or Province OH
Entity Address, Postal Zip Code 43017
City Area Code 614
Local Phone Number 757-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares (without par value)
Trading Symbol CAH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000721371
Amendment Flag false

JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20q38k33120form8-knew.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "cah-20200511_cal.xml" ] }, "definitionLink": { "local": [ "cah-20200511_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "a20q38k33120form8-knew.htm" ] }, "labelLink": { "local": [ "cah-20200511_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cah-20200511_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cah-20200511.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20200511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20q38k33120form8-knew.htm", "contextRef": "D2020Q3SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20q38k33120form8-knew.htm", "contextRef": "D2020Q3SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }